Can Novarel be used in patients with a history of uterine anomalies, and what adjustments are necessary to ensure treatment success?
How does Novarel influence the secretion of vascular endothelial growth factor (VEGF) during stimulation, and what are the implications for follicular angiogenesis?
Can Novarel be used in patients with a history of ovarian hyperstimulation syndrome (OHSS), and what precautions are necessary to minimize risks?
Can Novarel administration impact the success rates of donor embryo cycles, and how does it optimize the endometrial environment?
How does Novarel administration influence the timing and effectiveness of luteal phase defect correction in stimulated cycles?
How does Novarel influence the secretion of anti-Müllerian hormone (AMH) during ovarian stimulation, and what are the implications for ovarian reserve assessment?
What are the safety considerations for using Novarel in patients with uterine anomalies, and how does it impact uterine environment and implantation potential in these cases?
 
